Skip to main content

Month: March 2025

BHP announces exciting new role for its outgoing Chair

Birmingham Health Partners (BHP) has announced its Chair, Jonathan Pearson, will be stepping down at the end of his two-year term in September 2025, following his appointment as Chair of BHP member Health Innovation West Midlands (HIWM).

A highly experienced health business leader, Jonathan has chaired BHP for the past 18 months and has overseen significant progress and growth within the partnership – most notably, a new five-year strategy and the addition of Birmingham Community Healthcare NHS Foundation Trust as its ninth member.

Professor Lorraine Harper, Managing Director of BHP said: “We are incredibly grateful to Jonathan for his strategic leadership of BHP during a period of substantial change for our organisation, and look forward to continuing to work with him in his new role as Chair of our member HIWM.”

Professor Neil Hanley, Executive Director of BHP and Pro-Vice-Chancellor and Head of the College of Medicine and Health at the University of Birmingham, said: “I would also like to thank Jonathan for his hard work, enthusiasm and friendship over the last couple of years. Jonathan’s appointment to HIWM is a great opportunity to further strengthen relationships and partnerships across the West Midlands, and we are delighted that he will continue to contribute to Birmingham’s health and life sciences in his new role. He has a passion for healthcare innovation that sits at the heart of the Government’s ambitions for the NHS. We will soon begin our search for Jonathan’s successor, a process which will be led by Professor Sir Bruce Keogh.”

Jonathan commented: “I would like to thank the BHP Board, Neil, Lorraine and all the BHP team for their support and their excellent work in leading and reshaping the partnership over the last two years.  I wish BHP ongoing success and I look forward to continuing to work with the partnership in my new role.”

HIWM is one of 15 Health Innovation networks across England, working in partnership with NHS trusts, SMEs, care homes and universities to implement new healthcare and life sciences innovations at scale and pace. By enabling the healthcare system to take advantage of innovations that can help to save time, money and lives, HIWM is working to bring the West Midlands the future of health and social care, today.

Largest ever UK surgical trial aims to reduce post-surgery infections

More than £10m of funding from the National Institute for Health and Care Research (NIHR) has been awarded to BHP founder-member the University of Birmingham to run an ambitious trial which aims to recruit 26,000 patients from 100 sites across the UK in the next five years.

ROSSINI-Platform is a large multi-arm, multi-stage platform trial, led by Professor Thomas Pinkney and the Birmingham Clinical Trials Unit, that will help experts understand how to reduce wound infections that can occur following operations.

Wound infections, also referred to as Surgical Site Infections (SSI), are the commonest complication after surgery and affect up to one in four patients undergoing surgery each year. These infections carry an estimated cost to the NHS of at least £700m each year.

Professor Thomas Pinkney from the School of Health Sciences at the University of Birmingham, and Chief Investigator of the ROSSINI-Platform trial said: “An adult living in the UK will have an average of four operations during their lifetime. Up to a quarter of operations may result in a surgical site infection (SSI) – a post-operative infection of the wound – which can have significant negative impacts on patient recovery.

“We know that infections at different operation sites can cause different types of challenges. For example, an infection following a caesarean section can impact on the mothers’ ability to bond with their newborn. An infection following amputation could mean that the patient is no longer suitable to be fitted for a prosthetic, meaning they might become a wheelchair user.

“Post pandemic the waiting lists for surgeries are higher than ever, so an evidence-based approach to improving recovery times and reducing preventable complications and their associated risk of readmissions has never been more necessary.”

ROSSINI-Platform will look at various interventions to reduce the rates of surgical site infection, and the design of the trial will enable the team to focus on those that show evidence of benefit.

In total, 18 interventions are being assessed in the trial, with examples including:

  • using state-of-the-art wound cleaning solutions during surgery
  • using special wound dressings after surgery,
  • applying antibiotics differently during surgery,
  • changing gloves and instruments at certain points during surgery,
  • waxing or epilation around the surgical site

In addition, the trial will test these interventions across multiple operation types areas such as heart surgery, brain surgery, caesarean section and leg amputation, to find what works best to reduce infection in each setting.

Sue’s story

Sue Blackwell, 49, from Liverpool, has faced health issues over the years connected with inflammatory bowel disease and has had a total of 13 operations. Several operations have resulted in SSIs requiring antibiotics, but one infection led to unexpected complications that impacted Sue’s life for years.

Following a planned completion proctectomy, Sue developed a serious infection leading to being housebound for six months and losing control of her bladder for ten weeks.

Sue had to wait for district nurses to come and change her dressings twice each day, and this had a significant impact on her life. To add to the ordeal, Sue had to undergo additional surgeries to address the complications and experienced problems with wound draining for two years. The seemingly never-ending round of surgeries and treatments continued, and it took a total of eleven years for the wound to fully heal.

Sue is currently doing a PhD at the University of Birmingham and will use her lived experience to inform the ROSSINI-Platform trial as a public involvement representative.

Speaking of her involvement in both developing and delivering the study, Sue said:

“A lot of patients think that someone somewhere along the line is at fault, which isn’t usually the case. SSIs are very common and we don’t know enough about what we can do to stop them. With this trial, all the interventions are already in use, we know they are all safe, we’re just testing them against each other in a smart way, similar to a world cup tournament, to see which comes out on top.”

In addition to delaying or impeding patient recovery, SSIs are responsible for extending hospital stays and hospital readmissions. SSIs are a significant problem for the NHS, due to increased treatment costs and resource usage both in hospital and in the community. SSI is now the most common healthcare associated infection and costs the NHS at least £700million per year. It is therefore a priority for patients and the health service.

The trial team hope that the findings will help countries around the world to implement the most effective ways to prevent SSI following different types of common surgeries. This will help speed up recovery, get patients discharged from hospital sooner freeing up bed space, and in many countries around the world will save countless lives.

You might also be interested in: